Canada
· Delayed Price · Currency is CAD Algernon Pharmaceuticals Company Description
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company.
It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia.
The company’s pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries.
The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015.
Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Christopher Moreau |
Contact Details
Address: 601 West Broadway Vancouver, British Columbia V5Z 4C2 Canada | |
| Phone | 604 398 4175 |
| Website | algernonpharmaceuticals.com |
Stock Details
| Ticker Symbol | AGN |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | September - August |
| Reporting Currency | CAD |
| ISIN Number | CA01559R4008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher J. Moreau | Chief Executive Officer and Director |
| James F. Kinley C.A., CPA | Chief Financial Officer |
| Dr. Christopher Bryan Ph.D. | Vice President of Research and Operations |